β-Lactamases are enzymes that inactivate β-lactam antibiotics by catalyzing hydrolysis of their β-lactam ring. Produced by many kinds of bacteria, they are a major mechanism of antimicrobial resistance. Different β-lactamases act on different combinations of penicillins, cephalosporins, carbapenems, and monobactams. They constitute a diverse collection of enzyme families rather than a single enzyme with a uniform substrate range.
Biological function and mechanism
β-Lactam antibiotics interfere with bacterial cell-wall synthesis. Their principal targets are penicillin-binding proteins, including enzymes that cross-link peptidoglycan, a structural component of the bacterial wall. Opening the antibiotic’s β-lactam ring generally prevents it from effectively inhibiting these targets.
β-Lactamases catalyze cleavage of the ring’s carbon–nitrogen amide bond through the addition of water. Two major catalytic mechanisms occur:
- Serine β-lactamases use an active-site serine residue to attack the antibiotic, forming a covalent acyl–enzyme intermediate. Water subsequently hydrolyzes this intermediate, releasing the opened-ring product and regenerating the enzyme.
- Metallo-β-lactamases use one or two zinc ions, depending on the enzyme and conditions, to facilitate hydrolysis. They do not use the covalent serine intermediate characteristic of serine β-lactamases.
In Gram-negative bacteria, β-lactamases commonly act in the periplasm, the compartment between the inner and outer membranes. This positioning allows them to intercept antibiotics before the drugs reach their targets. In Gram-positive bacteria, β-lactamases may be secreted or remain associated with the cell envelope.
Resistance depends not only on an enzyme’s presence but also on its abundance, catalytic properties, and cellular context. Reduced antibiotic entry or increased drug export can act together with β-lactamase production.
Classification
Two complementary classification systems are widely used. The Ambler classification groups β-lactamases into molecular classes A, B, C, and D, principally on the basis of amino-acid sequence relationships. The Bush–Jacoby functional classification groups them according to substrate and inhibitor profiles. Molecular class and functional behavior are related, but they are not interchangeable.
| Ambler class | Catalytic mechanism | Representative enzymes | Characteristic activities |
|---|---|---|---|
| A | Active-site serine | TEM, SHV, CTX-M, KPC | Includes penicillinases, many extended-spectrum β-lactamases, and some carbapenemases |
| B | Zinc-dependent hydrolysis | NDM, VIM, IMP | Metallo-β-lactamases; many hydrolyze carbapenems |
| C | Active-site serine | AmpC-type enzymes | Commonly cephalosporinases, including enzymes active against cephamycins |
| D | Active-site serine | OXA-type enzymes | Includes oxacillinases and several important carbapenemase families |
Enzymes within one family can differ substantially in their activity. For example, some TEM and SHV variants have an extended substrate spectrum, whereas others do not. Similarly, the designation OXA does not by itself establish that an enzyme hydrolyzes carbapenems.
Extended-spectrum β-lactamases
Extended-spectrum β-lactamases (ESBLs) are generally defined functionally by their ability to hydrolyze expanded-spectrum cephalosporins and aztreonam. Most commonly encountered ESBLs belong to class A, particularly CTX-M enzymes and certain TEM and SHV variants. Many are inhibited by clavulanate under laboratory conditions.
Classical ESBLs generally do not efficiently hydrolyze cephamycins or carbapenems. Nevertheless, bacteria producing them may resist these drugs through additional mechanisms. ESBL terminology also varies somewhat between classification and laboratory frameworks.
AmpC β-lactamases
AmpC enzymes belong to class C. Their genes may occur on bacterial chromosomes or on plasmids. They commonly hydrolyze many penicillins and cephalosporins, including cephamycins, and are generally poorly inhibited by clavulanate.
In some species, chromosomal AmpC production is inducible. Regulatory changes can also cause sustained high-level production, often described as derepression. Consequently, resistance can change through altered gene expression without a corresponding change in the enzyme’s amino-acid sequence.
Carbapenemases
Carbapenemases are β-lactamases capable of hydrolyzing carbapenems. Clinically important examples occur in classes A, B, and D:
- KPC enzymes: class A serine carbapenemases.
- NDM, VIM, and IMP enzymes: class B metallo-β-lactamases.
- OXA-48-like enzymes and several OXA families associated with Acinetobacter: class D serine carbapenemases.
Carbapenem resistance does not necessarily demonstrate carbapenemase production. It can also arise through combinations of other β-lactamases and reduced outer-membrane permeability.
Genetics, evolution, and dissemination
β-Lactamase genes may be intrinsic to a bacterial species or acquired from another organism. They occur on chromosomes, plasmids, and other genetic structures associated with mobility. Horizontal gene transfer can spread them between bacterial strains and, in some cases, between species. Transposable elements and integrons help mobilize or assemble resistance determinants.
A gene’s location affects its potential for dissemination, but “chromosomal” and “acquired” are not mutually exclusive categories: an acquired resistance gene can become integrated into a chromosome.
Mutations can alter substrate recognition, catalytic efficiency, stability, or inhibitor susceptibility. Changes in regulatory regions or gene copy number can increase enzyme production. Antibiotic exposure can favor bacteria carrying advantageous resistance determinants through natural selection; it does not direct bacteria to produce a particular useful mutation.
β-Lactamases and related resistance determinants also occur in environmental microorganisms. Their evolutionary history predates clinical antibiotic use, although widespread antibiotic use has strongly influenced the selection and dissemination of resistant bacteria.
β-Lactamase inhibitors
β-Lactamase inhibitors are compounds that block particular β-lactamases, thereby protecting a partner antibiotic from degradation. Major examples include:
- Clavulanate, sulbactam, and tazobactam: older β-lactam-based inhibitors with activity against many class A enzymes, but limited activity against many class C and D enzymes.
- Avibactam and relebactam: diazabicyclooctane inhibitors active against selected serine β-lactamases. Their coverage differs; avibactam inhibits some class D enzymes, including OXA-48-like enzymes.
- Vaborbactam: a boron-containing inhibitor with important activity against class A KPC enzymes.
These examples do not provide comprehensive coverage of all enzyme variants. The inhibitors listed above do not reliably inhibit class B metallo-β-lactamases. Many metallo-β-lactamases do not efficiently hydrolyze aztreonam, but bacteria carrying them often also produce serine β-lactamases that do.
Inhibitor resistance can result from changes in the enzyme, increased enzyme production, or other cellular resistance mechanisms. Inhibitor activity against an isolated enzyme is therefore not equivalent to susceptibility of the whole bacterium.
Laboratory detection
Laboratories distinguish between the presence of resistance, β-lactamase activity, and the identity of a particular resistance determinant.
- Antimicrobial susceptibility testing measures bacterial growth in the presence of antibiotics and establishes the observed susceptibility profile.
- Activity assays detect antibiotic hydrolysis. Nitrocefin, a chromogenic cephalosporin, changes color when hydrolyzed and is widely used to demonstrate β-lactamase activity.
- Phenotypic differentiation tests use substrate patterns, inhibitor effects, or carbapenem-hydrolysis assays to investigate particular resistance mechanisms.
- Molecular methods, including polymerase chain reaction and DNA sequencing, detect or characterize β-lactamase genes.
- Immunochromatographic assays detect selected enzyme families through antibody recognition.
Each approach has limitations. A targeted molecular assay cannot exclude genes outside its target set, and detecting a gene does not establish its expression level. Conversely, a resistance phenotype may reflect several mechanisms acting together rather than one β-lactamase.
History and significance
In 1940, Edward Abraham and Ernst Chain reported a bacterial enzyme capable of destroying penicillin, before penicillin entered widespread clinical use. Subsequently, β-lactamase-mediated resistance became an important limitation of successive generations of β-lactam antibiotics.
β-Lactamases remain central to microbiology, antibiotic development, and public-health surveillance. Their clinical significance depends on the enzyme variant, the bacterial host, associated resistance mechanisms, and the antibiotic involved. Enzyme-family names alone are therefore insufficient to predict the full resistance profile of an isolate.